Global Prediabetes Market Growth, Size, Trends Analysis - By Drug Class, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Global Prediabetes Market Introduction and Overview

According to SPER market research, 'Global Prediabetes Market Size- By Drug Class, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Prediabetes Market is predicted to reach 1021.93 million by 2034 with a CAGR of 11.19%.

Prediabetes is a medical condition in which blood sugar levels are elevated above the normal range but not high enough to be classified as type 2 diabetes. Fasting blood glucose levels typically range from 100 to 125 mg/dL in individuals with prediabetes. This condition suggests early issues with blood sugar regulation, often resulting from insulin resistance.

Restraints: The global prediabetes market faces a number of obstacles that limit its overall growth. A key issue is the high rate of underdiagnosis, as prediabetes often lacks noticeable symptoms, leaving many individuals unaware they are affected. This is further exacerbated by low public awareness and inadequate routine screening, especially in low-resource and developing regions.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Drug Class, By Age Group

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Novo Nordisk A/S, Valbiotis, RESVERLOGIX, Caelus Health, Scimar, Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc.

Global Prediabetes Market Segmentation:

By Drug Class: Based on the Drug Class, Global Prediabetes Market is segmented as; Diguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others.

By Age Group: Based on the Age Group, Global Prediabetes Market is segmented as; {(Children (12-18 years), Adults (18-49), Elderly (50+).

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25145

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Prediabetes Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Prediabetes Market

7. Global Prediabetes Market, By Drug Class, (USD Million) 2021-2034

7.1. Diguanide
7.2. Thiazolidinediones
7.3. Glucagon-like peptide-1 agonists (GLP-1)
7.4. SGLT2 inhibitors
7.5. DPP-4 inhibitors
7.6. Others

8. Global Prediabetes Market, By Age Group, (USD Million) 2021-2034

8.1. Children (12-18 years)
8.2. Adults (18-49)
8.3. Elderly (50+)

9. Global Prediabetes Market, (USD Million) 2021-2034

9.1. Global Prediabetes Market Size and Market Share

10. Global Prediabetes Market, By Region, 2021-2034 (USD Million)

10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America

11. Company Profile

11.1. Novo Nordisk A/S
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Valbiotis
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. RESVERLOGIX
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Caelus Health
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Scimar
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Boston Pharmaceuticals
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. APHAIA PHARMA AG
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. AstraZeneca
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Bristol-Myers Squibb Company
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Pfizer Inc.
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Others